Founder or Colony-Bred? What Pre-Study Immunophenotyping Actually Shows

As responsible sourcing becomes a bigger part of how sponsors plan nonhuman primate (NHP) studies, one question comes up more often: does an animal's origin — imported founder stock (F0) versus colony-bred offspring (F1) — change anything about how it performs as a study subject? It's a reasonable thing to wonder. Founder and colony-bred animals often come from different supply chains, different early-life environments, and sometimes different geographic origins. If those differences showed up in baseline immune status, it would matter a great deal for cohort design.

So we looked at what pre-study immunophenotyping actually shows.

Why baseline immune status matters before a study even starts

Every NHP cohort carries some degree of natural biological variability — that's true regardless of origin. The purpose of pre-study immunophenotyping isn't to eliminate that variability; it's to document it, so a sponsor knows what a cohort looks like immunologically before dosing begins. A multi-parameter flow cytometry panel run at baseline typically covers three layers of resolution:

• Major lymphocyte lineages — T cells, B cells, and NK cells as a proportion of the live lymphocyte population

• B cell maturation subsets — naïve, unswitched, switched, activated memory, and resting memory

• T cell memory phenotyping — central memory, effector memory, and naïve populations within both the CD4+ and CD8+ compartments

That level of detail is what lets a study team catch an outlier animal at baseline instead of discovering it mid-study — and it's also what makes it possible to actually answer the F0-vs-F1 question with data instead of assumption.

What the data shows

Looking at a representative pre-study immunophenotyping pattern across founder-origin and colony-bred cohorts, the two groups track closely across every major measure — lymphocyte frequency, T cell proportion, B cell proportion, and NK cell proportion all fall within overlapping ranges, with no consistent directional shift by origin.

Where F0 and F1 typically don't differ

Pulling the full panel apart — not just the four headline lineage measures, but the maturation and memory-phenotype detail underneath them — the pattern holds:

• Overall lineage balance. T cell, B cell, and NK cell proportions land in the same general range regardless of animal origin.

• CD4:CD8 ratio. Helper and cytotoxic T cell balance tracks together across founder-origin and colony-bred cohorts.

• B cell maturation. The naïve-to-memory split shows no consistent generational pattern.

• T cell memory phenotype. Central memory, effector memory, and naïve proportions move together between groups.

In other words, generation doesn't appear to be a meaningful axis of immune variability on its own — at least not one that shows up ahead of the variability you'd expect to see between any two animals in a cohort.

What this means for cohort design

For sponsors weighing sourcing strategy alongside study design, this is a useful data point: choosing colony-bred animals for reasons of supply reliability or responsible sourcing doesn't appear to come at the cost of a different immune starting point. The variability that does matter — the animal-to-animal spread within a cohort — is exactly what pre-study immunophenotyping is built to catch, regardless of where any individual animal came from.

That's the actual value of running this kind of panel before a study begins: not to rule origin in or out as a factor, but to replace an assumption with a documented answer, and to flag the animals (of either origin) that fall outside the expected range before they become a variable in your data.

A documented baseline, either way

None of this means every immunophenotyping panel will land the same way — biological variability is real, and every cohort deserves its own baseline characterization rather than an inherited assumption. But it does suggest that origin alone is not the variable to worry about. The variable worth watching is the individual animal.

If you're planning a discovery-stage NHP study and want to talk through what a baseline immunophenotyping panel could look like for your program, get in touch with ANEWCRO.